Patología Intestinal Referencias 1.- Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23: 529-49. 2.- Barra-Carrasco J, Hernández-Rocha C, Ibáñez P, Guzmán-Durán AM, Álvarez- Lobos M, Paredes-Sabja D. Clostridium difficile spores and its relevance in the persistence and transmission of the infection. Rev Chilena Infectol 2014; 31: 694-703. 3.- Hernández-Rocha C, Pidal P, Ajenjo MC, Quera R, Quintanilla M, Lubascher J, et al. Chilean consensus of prevention, diagnosis and treatment of Clostridium difficile-associated diarrhea. Rev Chilena Infectol 2016; 33: 98-118. 4.- Jarrad AM, Karoli T, Blaskovich MA, Lyras D, Cooper MA. Clostridium difficile drug pipeline: challenges in discovery and development of new agents. J Med Chem 2015; 58: 5164-85. 5.- Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44: 846-8. 6.- Di X, Bai N, Zhang X, Liu B, Ni W, Wang J, et al. A meta-analysis of metronidazole and vancomycin for S 36 Terapia en infecci ón p or Clostridium difficile - C. Hernández-Rocha the treatment of Clostridium difficile infection, stratified by disease severity. Braz J Infect Dis 2015; 19: 339-49. 7.- Bass SN, Lam SW, Bauer SR, Neuner EA. Comparison of oral vancomycin capsule and solution for treatment of initial episode of severe Clostridium difficile Infection. J Pharm Pract 2015; 28: 183-8. 8.- Rokas KE, Johnson JW, Beardsley JR, Ohl CA, Luther VP, Williamson JC. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. Clin Infect Dis 2015; 61: 934- 41. 9.- Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficileassociated disease in Quebec, Canadá. Clin Infect Dis 2006; 42: 758-64. 10.- McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-75. 11.- van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-15. 12.- Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014; 48: 693-702. 13.- Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014; 109: 1065-71. 14.- Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9: 1044-9. 15.- Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 2014; 69: 2892-900. 16.- Musgrave CR, Bookstaver PB, Sutton SS, Miller AD. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. Int J Infect Dis 2011; 15: e438-48. Gastroenterol. latinoam 2016; Vol 27, S upl Nº 1: S 32-S 36
Gastro_3
To see the actual publication please follow the link above